IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# NATURAL PRODUCTS AS POTENTIAL TREATMENTS FOR NEURODEGENERATIVE DISEASES: ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE.

**Monali B. Parabhane[1st], Bhise Ajay Santosh[2nd], Bhange Rahul Atul[3rd], Adsul Pranali Sadanand[4th].**

SCSSS's Sitabai Thite Collage of Pharmacy, Shirur (Pune) – 412210

[1st-] Department of Pharmaceutics

## Abstract:

Neurodegenerative diseases (NDDs) are a group of disorders that result in progressive loss of neurons and their functions. Currently, there is no cure for NDDs, and the available treatments are mostly focused on managing symptoms. However, natural products have shown promise as potential treatments for NDDs due to their ability to modulate multiple targets and their safety profile. In this review, we summarize the current state of research on natural products as potential treatments for NDDs, including their mechanisms of action, preclinical and clinical studies, and future directions. We highlight the potential of natural products as a source of novel therapeutics for NDDs and the need for further research to better understand their therapeutic potential. Neurodegenerative diseases (NDDs) are a group of disorders characterized by the progressive loss of neurons and their functions. They include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), among others. NDDs affect millions of people worldwide and pose a significant burden on healthcare systems.

The current treatments for NDDs are mostly focused on managing symptoms, and there is no cure for these diseases. However, natural products have shown promise as potential treatments for NDDs due to their ability to modulate multiple targets and their safety profile. Natural products are chemical compounds derived from plants, animals, or microorganisms, and they have been used for centuries in traditional medicine to treat various ailments. Several natural products have been studied for their potential to treat NDDs. Resveratrol, a polyphenol found in grapes and red wine, has also been shown to have neuroprotective properties and can improve cognitive function in animal models of AD.

**Keywords:** *Neurodegenerative Diseases, neurodegenerative diseases, natural products, potential treatments, resveratrol, EGCG, antioxidant, anti-inflammatory, alpha-synuclein, ginkgo biloba, ashwagandha, neuroprotection, cognitive function.*

## 1. Introduction

Neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of neurons in specific regions of the brain, leading to a decline in cognitive and motor function. Current treatments for these diseases are limited and often have significant side effects, highlighting the need for new and effective therapies. Natural products, such as polyphenols, alkaloids, and terpenoids, have shown promise as potential treatments for neurodegenerative diseases due to their ability to modulate various signaling pathways and protect against oxidative stress and inflammation.

Neurodegenerative diseases are a group of debilitating disorders that affect millions of people worldwide. They are characterized by the gradual and irreversible loss of neurons in specific regions of the brain, leading to a decline in cognitive and motor function. The most common neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. These diseases have a significant impact on the quality of life of patients and their families and pose a significant economic burden on healthcare systems. Currently, available treatments for these diseases are limited and often have significant side effects. Therefore, there is an urgent need for new and effective therapies for these devastating diseases. In recent years, natural products have emerged as potential treatments for neurodegenerative diseases. Natural products are chemical compounds derived from plants, animals, or microorganisms that have been used for centuries in traditional medicine to treat various ailments. They have been shown to have a wide range of pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. Several natural products, including polyphenols, alkaloids, and terpenoids, have been extensively studied for their potential to treat neurodegenerative diseases. These compounds have been shown to modulate various signaling pathways involved in neurodegeneration, protect against oxidative stress and inflammation, and promote neuronal survival and function.

Overall, natural products represent a promising avenue for the development of new and effective therapies for neurodegenerative diseases. However, further research is needed to better understand the mechanisms of action of these compounds and to develop effective therapies for these devastating diseases [Fig.1]




**fig.1 molecular basis of neurodegeneration: Alzheimer and Parkinson disease.**

**Table 1. Representative natural products and their bioactive substances with neuroprotective activity.**

| Name of Plant Part | Name of Model | Neuroprotective Mechanism |
|---|---|---|
| Yacon (Poepp. and endl.) extract of the leaf | Rat | Memory deficits prevented |
| Natural Sunflower aqueous extract | Rat | Short and long term memory improved |
| Methanolic extract of *Lactucacapensis* thumb. Leaves | Rat | Lowering the degree of lipid peroxidation and protein oxidation |
| Turmeric powder | Human | Improvement in the quality of life and behavioral symptoms |
| *Tabernaemontana divaricata* root extract | Mouse | Prevented memory loss |
| Coconut oil enriched Mediterranean diet | Human | Enhanced cognitive features |
| Osmotin, a protein derived from *Nicotiana tabacum* | Mouse | Increased conduct of random alteration |
| Germinated brown rice | SH-SY5Y cells | Reduced production of intracellular ROS |

| | | |
|---|---|---|
| Huperzine A isolated from *Huperzia serrata* | Rat | Reduce oxidative damage |

## 2. Mechanisms of Action

Natural products have been shown to exert their neuroprotective effects through various mechanisms, including the modulation of neuroinflammation, oxidative stress, and the accumulation of misfolded proteins. For example, polyphenols such as resveratrol and curcumin have been shown to inhibit the formation of beta-amyloid plaques and tau tangles, which are hallmarks of Alzheimer's disease. Other natural products, such as ginkgo biloba and HUPERZINE A, have been shown to enhance cholinergic neurotransmission, which is impaired in Alzheimer's disease.

Many natural products have been found to have neuroprotective properties, which may make them effective in the treatment of neurodegenerative diseases. For example, curcumin, the active ingredient in turmeric, has anti-inflammatory, antioxidant, and anti-amyloid properties, all of which may help to protect against Alzheimer's disease. Similarly, flavonoids, found in many fruits and vegetables, have the ability to enhance neuronal function and increase blood flow to the brain.

In addition to their neuroprotective effects, natural products may modulate key signaling pathways involved in neurodegeneration. Some natural products activate the Nrf2-ARE pathway, which regulates antioxidant and detoxification genes. Others inhibit the activity of enzymes involved in the production of reactive oxygen species (ROS), which contribute to neurodegeneration. One of the advantages of natural products is their ability to target multiple pathways involved in neurodegeneration. For example, resveratrol, a polyphenol found in red wine, activates SIRTUINS, proteins involved in cellular metabolism and stress response. Resveratrol also inhibits the formation of amyloid beta aggregates, characteristic of Alzheimer's disease. Another example is epigallocatechin-3-gallate (EGCG), a polyphenol found in green tea, which inhibits the aggregation of alpha-synuclein, a protein involved in Parkinson's disease. Additionally, natural products act as antioxidants and anti-inflammatory agents, reducing oxidative stress and inflammation, processes implicated in the pathogenesis of neurodegenerative diseases. Curcumin has antioxidant and anti-inflammatory properties and inhibits the formation of amyloid beta aggregates [Fig.2]




**fig.2 common mechanism of neurodegeneration.**

## 3. Bioavailability and Toxicity

Bioavailability and toxicity are important considerations in the development of natural products as potential treatments for neurodegenerative diseases. Bioavailability refers to the amount of a compound that is able to enter systemic circulation and reach the target tissues, while toxicity refers to the potential adverse effects that a compound may have on the body. Natural products are known to have low bioavailability due to their poor solubility, stability, and absorption in the gastrointestinal tract. This can limit their therapeutic efficacy and require higher doses to achieve the desired effect. However, advances in drug delivery systems such as nanoparticles, liposomes, and cyclodextrins have been developed to enhance the bioavailability of natural products.

In addition, some natural products have been found to have poor oral bioavailability, but high levels of absorption through other routes such as inhalation or topical administration. For example, essential oils from plants such as lavender, peppermint, and rosemary have been shown to have neuroprotective effects when inhaled, and topical application of certain plant extracts such as ginkgo biloba has been found to improve cognitive function in patients with dementia. Toxicity is another important consideration in the development of natural products as potential treatments for neurodegenerative diseases. While natural products are generally considered safe, they can still have adverse effects at high doses or when taken with certain medications. For example, St. John's Wort, a natural product commonly used for depression, can interact with antidepressant drugs and cause serotonin syndrome, a potentially life-threatening condition.

Toxicity can also be a concern with natural products that contain heavy metals, such as lead or mercury, which can accumulate in the body over time and cause neurological damage. Therefore, it is important to ensure that natural products are tested for heavy metal contamination and that their manufacturing processes are in compliance with good manufacturing practices. Another potential source of toxicity with natural products is their interaction with the cytochrome P450 enzymes, which are responsible for metabolizing many drugs and natural products in the liver. Some natural products can induce or inhibit these enzymes, leading to changes in the metabolism of other drugs and potential adverse effects. Therefore, it is important to be aware of these potential interactions and to monitor patients for any adverse effects when combining natural products with other medications.

Another factor that can affect the bioavailability of natural products is their metabolism. Many natural products undergo significant metabolism in the liver and other organs, which can reduce their effectiveness and bioavailability. In some cases, metabolism can even result in the production of toxic metabolites. Therefore, understanding the metabolic pathways of natural products is important for optimizing their bioavailability and minimizing toxicity. Toxicity is another important consideration when developing natural products as potential treatments for neurodegenerative diseases. While natural products are generally considered to be safer than synthetic drugs, they can still have toxic effects, especially at high doses or with prolonged use. Toxicity can manifest in a variety of ways, including organ damage, immune suppression, and interference with normal physiological processes. One approach to minimizing toxicity is to identify and isolate the specific compounds responsible for the therapeutic effects of natural products. By isolating these compounds, researchers can reduce the risk of toxicity and optimize their therapeutic potential. For example, the compound curcumin, which is found in turmeric, has been shown to have neuroprotective effects in preclinical studies. However, curcumin has low bioavailability and can be metabolized into potentially toxic compounds. To address these issues, researchers have developed derivatives of curcumin that are more bioavailable and less toxic, while still retaining their neuroprotective properties. Another approach to minimizing toxicity is to combine natural products with other compounds or therapies that can enhance their therapeutic effects or reduce their toxic effects. For example, some natural products have been found to enhance the efficacy of chemotherapy drugs in cancer treatment, while others have been found to reduce the toxic side effects of chemotherapy. Similarly, combining natural products with lifestyle interventions such as exercise and diet may also enhance their therapeutic effects and reduce toxicity.

In conclusion, the bioavailability and toxicity of natural products are important considerations when developing them as potential treatments for neurodegenerative diseases. Optimization of bioavailability through formulation, delivery systems, and metabolic pathway understanding can maximize therapeutic potential, while minimizing toxicity. The identification and isolation of specific compounds, as well

as combination therapies, can also reduce the risk of toxicity and enhance therapeutic efficacy. Further research is needed to fully understand the bioavailability and toxicity of natural products and their potential as treatments for neurodegenerative diseases.

## 4. Preclinical Studies

Preclinical studies play an important role in the development of natural products as potential treatments for neurodegenerative diseases. These studies are conducted to assess the safety and efficacy of natural products before they are tested in humans. In this section, we will discuss some of the key findings from preclinical studies of natural products for neurodegenerative diseases. Preclinical studies have demonstrated that natural products can have a variety of effects on the brain, including antioxidant, anti-inflammatory, and neuroprotective effects. For example, curcumin, the active ingredient in turmeric, has been shown to have neuroprotective effects in animal models of Alzheimer's disease. In one study, rats that were injected with a compound that causes Alzheimer's-like symptoms were treated with curcumin. The results showed that curcumin reduced inflammation in the brain and improved cognitive function in the rats. Similarly, resveratrol, a polyphenol found in red wine, has been shown to have neuroprotective effects in animal models of Parkinson's disease. In one study, mice that were injected with a compound that causes Parkinson's-like symptoms were treated with resveratrol. The results showed that resveratrol protected against the loss of dopamine-producing neurons in the brain, which is a hallmark of Parkinson's disease.

In addition to their neuroprotective effects, natural products have also been shown to have the ability to modulate key signaling pathways involved in neurodegeneration. For example, some natural products have been found to activate the Nrf2-ARE pathway, which is involved in the regulation of antioxidant and detoxification genes. Others have been found to inhibit the activity of enzymes that are involved in the production of reactive oxygen species (ROS), which can contribute to neurodegeneration. Preclinical studies have also been conducted to assess the safety and toxicity of natural products. While natural products are generally considered safe, some can have toxic effects if taken in high doses or for prolonged periods of time. For example, high doses of green tea extract have been shown to cause liver toxicity in some animal studies. Similarly, high doses of ginkgo biloba extract have been shown to cause bleeding disorders in some animal studies. However, it should be noted that these toxic effects are rare and typically only occur at doses that are much higher than those used in humans.

One challenge in preclinical studies is the lack of standardization of natural products. Unlike synthetic drugs, natural products can vary widely in their chemical composition, which can make it difficult to compare results across studies. To address this issue, efforts are underway to develop standardized extracts of natural products that can be used in preclinical and clinical studies. The preclinical studies have provided valuable information on the efficacy and safety of natural products in the treatment of neurodegenerative diseases. However, there are several limitations to preclinical studies that need to be considered when interpreting the results.

One of the main limitations of preclinical studies is the use of animal models, which may not accurately reflect the human disease. Animal models may not fully replicate the complex pathophysiology of neurodegenerative diseases, and there may be differences in drug metabolism and pharmacokinetics between animals and humans. Another limitation is the lack of standardization in study design and outcome measures. There is often variability in the doses, formulations, and administration routes used in preclinical studies, which can make it difficult to compare results across studies. Additionally, the outcome measures used to assess efficacy and toxicity may not be standardized, which can make it difficult to interpret the results.

Despite these limitations, preclinical studies are a crucial step in the drug development process, as they provide important information on the efficacy and safety of natural products. Preclinical studies can help to identify promising natural products for further development, and can also provide valuable information on the optimal dosing, formulation, and administration route for clinical trials. Overall, preclinical studies have demonstrated the potential of natural products as treatments for neurodegenerative diseases. However, further research is needed to fully understand the efficacy and safety of these products in humans, and to address the limitations of preclinical studies.

In conclusion, preclinical studies have demonstrated the potential of natural products as treatments for neurodegenerative diseases. These studies have shown that natural products can have neuroprotective, anti-inflammatory, and antioxidant effects, as well as the ability to modulate key signaling pathways involved in neurodegeneration. However, more research is needed to better understand the safety and efficacy of natural products, as well as to develop standardized extracts for use in preclinical and clinical studies.

## 5. Novel Natural Products

In recent years, researchers have identified and characterized several novel natural products with potential neuroprotective activity. For example, baicalin, a flavonoid isolated from SCUTELLARIA BAICALENSIS, has been shown to protect against neuroinflammation and cognitive impairment in animal models of Alzheimer's disease. Another example is ROSMARINIC acid, a phenolic acid found in rosemary, which has been shown to improve cognitive function and protect against oxidative stress in animal models of Parkinson's disease. The search for novel natural products for the treatment of neurodegenerative diseases has been ongoing for several decades, with the aim of identifying new compounds with improved efficacy and reduced toxicity. In recent years, several promising natural products have been identified that show potential as treatments for neurodegenerative diseases.

One such natural product is cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant. CBD has been shown to have anti-inflammatory and neuroprotective effects in preclinical studies, and several clinical trials have been conducted to evaluate its efficacy in the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's disease. Although the results of these trials have been mixed, CBD remains a promising natural product for the treatment of neurodegenerative diseases. Another promising natural product is baicalein, a flavonoid found in the roots of the Chinese skullcap plant. Baicalein has been shown to have antioxidant and anti-inflammatory effects, and to protect against neuronal cell death in preclinical studies. Several studies have also shown that baicalein can improve cognitive function in animal models of Alzheimer's disease. Baicalein has the potential to be developed into a novel natural product for the treatment of neurodegenerative diseases.

*Ginkgo biloba* is another natural product that has been studied extensively for its potential to treat neurodegenerative diseases. *Ginkgo biloba* extract contains several compounds, including flavonoids and terpenoids, that have antioxidant and anti-inflammatory effects. Several preclinical studies have shown that *Ginkgo biloba* extract can improve cognitive function and protect against neuronal cell death in animal models of Alzheimer's and Parkinson's disease. However, clinical trials have produced mixed results, and further research is needed to fully understand the efficacy and safety of *Ginkgo biloba* extract as a treatment for neurodegenerative diseases.

In addition to these natural products, there are several others that show promise as potential treatments for neurodegenerative diseases. For example, curcumin, the active ingredient in turmeric, has been shown to have anti-inflammatory and antioxidant effects, as well as the ability to inhibit the formation of amyloid beta aggregates, which are characteristic of Alzheimer's disease. Another natural product, epigallocatechin-3-gallate (EGCG), found in green tea, has been shown to inhibit the aggregation of alpha-synuclein, a protein involved in Parkinson's disease.

Overall, the search for novel natural products for the treatment of neurodegenerative diseases is ongoing, and several promising compounds have been identified. These compounds have the potential to provide new treatments for these devastating diseases, and further research is needed to fully understand their efficacy and safety in humans. In addition to the natural products mentioned in previous sections, there are many other novel natural products that show potential as treatments for neurodegenerative diseases. Here are some examples:

1. Polydatin: Polydatin is a stilbenoid found in the roots of Polygonum cuspidatum, also known as Japanese knotweed. It has been shown to have neuroprotective effects in animal models of Alzheimer's disease, Parkinson's disease, and cerebral ischemia.

Polydatin works by reducing oxidative stress and inflammation, as well as by promoting neurogenesis.

2. 3-N-butylphthalide (NBP): NBP is a natural product found in the seeds of Apium graveolens, also known as celery. It has been shown to have neuroprotective effects in animal models of stroke, Alzheimer's disease, and Parkinson's disease. NBP works by reducing oxidative stress and inflammation, as well as by promoting the production of brain-derived neurotrophic factor (BDNF), a protein that supports the survival and growth of neurons.

3. Ginkgolide B: Ginkgolide B is a terpene lactone found in the leaves of Ginkgo biloba. It has been shown to have neuroprotective effects in animal models of Alzheimer's disease, cerebral ischemia, and traumatic brain injury. Ginkgolide B works by reducing oxidative stress and inflammation, as well as by inhibiting the activity of certain enzymes that contribute to neurodegeneration.

4. Baicalein: Baicalein is a flavonoid found in the roots of SCUTELLARIA BAICALENSIS, also known as Chinese skullcap. It has been shown to have neuroprotective effects in animal models of Alzheimer's disease, Parkinson's disease, and cerebral ischemia. Baicalein works by reducing oxidative stress and inflammation, as well as by inhibiting the activity of certain enzymes that contribute to neurodegeneration.

5. Ursolic acid: Ursolic acid is a triterpenoid found in many fruits and vegetables, including apples, blueberries, and rosemary. It has been shown to have neuroprotective effects in animal models of Alzheimer's disease, Parkinson's disease, and cerebral ischemia. Ursolic acid works by reducing oxidative stress and inflammation, as well as by promoting neurogenesis and inhibiting the activity of certain enzymes that contribute to neurodegeneration.

These novel natural products represent exciting new avenues for the development of treatments for neurodegenerative diseases. Further research is needed to fully understand their mechanisms of action and potential therapeutic benefits [Fig.3]

**fig.3 drug discovery from natural sources**

## 6. Combination and Derivatives

In addition to identifying and characterizing novel natural products, researchers are also exploring the use of natural product combinations and derivatives to improve efficacy and reduce toxicity. For example, a combination of resveratrol and quercetin has been shown to reduce amyloid beta accumulation and improve cognitive function in mouse models of Alzheimer's disease. Another example is EGB 761, a standardized extract of Ginkgo biloba that contains several active compounds, including terpenoids and flavonoids. EGB 761 has been shown to improve cognitive function and reduce oxidative stress in patients with Alzheimer's disease.

Combination and derivatives of natural products offer a promising approach to enhance the therapeutic efficacy and reduce toxicity associated with single agents. The use of natural product combinations can result in synergistic effects and increase the potency of the treatment. Furthermore, natural product derivatives can be designed to improve the bioavailability, stability, and specificity of the compound.

One example of a natural product combination that has shown promise in the treatment of neurodegenerative diseases is the combination of curcumin and Piperine. Curcumin, the active ingredient in turmeric, has been shown to have neuroprotective properties, but its bioavailability is limited. Piperine, a compound found in black pepper, has been shown to enhance the bioavailability of curcumin. Studies have shown that the combination of curcumin and piperine can improve cognitive function and reduce oxidative stress in animal models of Alzheimer's disease. Another example of a natural product combination is the combination of ginseng and Ginkgo biloba. Both of these natural products have been shown to have cognitive-enhancing effects and to protect against neurodegeneration. Studies have shown that the combination of ginseng and Ginkgo biloba can improve cognitive function in healthy individuals and in patients with Alzheimer's disease.

Natural product derivatives can also be designed to improve the therapeutic efficacy of the compound. One example is the development of analogs of resveratrol, a polyphenol found in red wine. Resveratrol has been shown to have neuroprotective properties, but its poor bioavailability limits its clinical use. Researchers have developed resveratrol analogs that have improved bioavailability and enhanced neuroprotective effects.

In addition to natural product combinations and derivatives, researchers are also exploring the use of natural products as adjuvants to enhance the efficacy of other treatments. For example, curcumin has been shown to enhance the efficacy of chemotherapy in the treatment of glioblastoma, a type of brain cancer. Similarly, green tea catechins have been shown to enhance the efficacy of radiation therapy in the treatment of prostate cancer. Overall, the use of natural product combinations and derivatives offers a promising approach to enhance the therapeutic efficacy and reduce toxicity associated with single agents. Furthermore, natural products can be used as adjuvants to enhance the efficacy of other treatments, highlighting their potential as a complementary therapy in the treatment of neurodegenerative diseases. However, more research is needed to fully understand the mechanisms of action and potential side effects of natural product combinations and derivatives.

Several studies have focused on developing natural product derivatives with improved pharmacological properties compared to the parent compounds. One approach is to modify the chemical structure of the natural product to enhance its bioavailability and/or target specificity. For example, a modified version of curcumin called THERACURMIN has been developed that improves its bioavailability by encapsulating the compound in a nanoparticle. This modification has been shown to enhance curcumin's neuroprotective effects in preclinical models of neurodegenerative diseases. Another approach is to combine natural products with synthetic compounds or other natural products to create novel molecules with enhanced pharmacological properties. For example, researchers have developed a series of hybrid molecules by combining resveratrol with various other compounds, including ferulic acid, benzothiazole, and tamoxifen. These hybrid molecules have been shown to have improved antioxidant and anti-inflammatory activities compared to resveratrol alone, as well as increased neuroprotective effects in preclinical models of neurodegenerative diseases. In addition to modifying natural products or combining them with other compounds, researchers are also exploring the use of natural product combinations to enhance their therapeutic potential. For example, a combination of epigallocatechin gallate (EGCG) and baicalein, two natural products with neuroprotective properties, has been shown to improve cognitive function and reduce amyloid beta accumulation in mouse models of Alzheimer's disease. Similarly, a combination of honokiol and magnolol, two compounds found in Magnolia officinalis, has been shown to have synergistic neuroprotective effects in preclinical models of Parkinson's disease.

Overall, the development of natural product derivatives and combinations represents a promising avenue for the development of new and effective therapies for neurodegenerative diseases. These approaches can improve the pharmacological properties of natural products, enhance their efficacy, and reduce their toxicity, potentially leading to better clinical outcomes for patients.

## 7. Clinical Trials

Several natural products have progressed to clinical trials for the treatment of neurodegenerative diseases, although results have been mixed. For example, a phase III clinical trial of curcumin for the treatment of mild-to-moderate Alzheimer's disease did not show significant benefits compared to placebo. However, other trials have shown promising results. A phase II trial of resveratrol for the treatment of mild-to-moderate Alzheimer's disease showed a significant reduction in amyloid beta levels in the cerebrospinal fluid of treated patients compared to placebo. Similarly, a phase II trial of ginkgo biloba for the treatment of mild cognitive impairment showed significant improvements in cognitive function compared to placebo. Clinical trials are essential to assess the safety and efficacy of potential natural product treatments for neurodegenerative diseases in humans. Several clinical trials have been conducted to investigate the therapeutic potential of natural products, including curcumin, resveratrol, ginkgo biloba, and green tea.

One of the most extensively studied natural products is curcumin, a polyphenol derived from turmeric. A phase II clinical trial investigated the safety and efficacy of a curcumin formulation in patients with mild-to-moderate Alzheimer's disease. The trial found that curcumin was well-tolerated and led to significant improvements in cognitive function and mood. However, larger and longer-term trials are needed to confirm these findings and determine the optimal dose and formulation of curcumin for Alzheimer's disease.

*Resveratrol*, a polyphenol found in grapes and red wine, has also been studied extensively in clinical trials for its potential neuroprotective effects. A phase II clinical trial investigated the safety and efficacy of a resveratrol formulation in patients with mild-to-moderate Alzheimer's disease. The trial found that resveratrol was safe and well-tolerated and led to improvements in cognitive function and biomarkers of Alzheimer's disease. However, larger and longer-term trials are needed to confirm these findings and determine the optimal dose and formulation of resveratrol for Alzheimer's disease.

*Ginkgo biloba*, a plant extract that has been used in traditional Chinese medicine for centuries, has been found to have neuroprotective effects in animal studies. Several clinical trials have investigated the efficacy of ginkgo biloba in the treatment of Alzheimer's disease. While some studies have reported positive results, others have been inconclusive. Further studies are needed to determine the efficacy and safety of ginkgo biloba in the treatment of Alzheimer's disease.

*Green tea*, which contains several polyphenols that have been found to have antioxidant and anti-inflammatory effects, has also been investigated in clinical trials for its potential neuroprotective effects. A randomized controlled trial investigated the effects of green tea extract on cognitive function in healthy adults. The trial found that green tea extract improved cognitive function, particularly in tasks related to working memory. However, more studies are needed to determine the optimal dose and formulation of green tea extract for neurodegenerative diseases.

In conclusion, clinical trials have shown promising results for the use of natural products in the treatment of neurodegenerative diseases, particularly curcumin and resveratrol. However, larger and longer-term studies are needed to confirm these findings and determine the optimal dose and formulation of natural products for neurodegenerative diseases. Another natural product that has shown promise in clinical trials is Bacopa monnieri, a herb commonly used in Ayurvedic medicine for memory enhancement. In a randomized, double-blind, placebo-controlled trial, elderly participants with memory impairment were given Bacopa monnieri

extract for 12 weeks. The results showed significant improvements in cognitive function, including memory recall and information processing speed, compared to the placebo group.

In addition to single natural products, researchers are also investigating the use of natural product combinations in clinical trials. For example, a randomized, double-blind, placebo-controlled trial of a combination of omega-3 fatty acids and curcumin in patients with mild-to-moderate Alzheimer's disease found that the combination led to significant improvements in cognitive function and reduced amyloid beta levels in the brain. Despite promising results, it is important to note that many natural product clinical trials have limitations, such as small sample sizes and short treatment durations. Furthermore, the lack of standardization in natural product preparations and the variability in bioavailability and efficacy can also pose challenges for clinical trial design and interpretation of results.

Overall, clinical trials of natural products for neurodegenerative diseases are still in the early stages, and further research is needed to fully understand their potential benefits and limitations. However, the promising results so far suggest that natural products may have a role to play in the development of effective treatments for these devastating conditions [Fig.4]




**fig.4 clinical trials and drug development of Alzheimer's disease.**

## 8. Drug Development

While natural products have shown promise in the treatment of neurodegenerative diseases, there are several challenges associated with their use as drugs. One of the main challenges is the fact that natural products are often complex mixtures of compounds, which can make it difficult to identify the active ingredient responsible for the observed effects. Another challenge is the fact that natural products may have poor bioavailability, which can limit their effectiveness as drugs. To overcome these challenges, researchers may need to modify natural products or develop synthetic analogs that are more potent and have better pharmacokinetic properties.

Finally, natural products may be subject to contamination or adulteration, which can compromise their safety and efficacy. Quality control measures, such as the use of standardized extracts and analytical methods, may be necessary to ensure the safety and consistency of natural product-based drugs.

Overall, natural products offer a promising area of research for the development of treatments for neurodegenerative diseases. While there are several challenges associated with their use as drugs, advances in pharmacognosy, chemistry, and clinical medicine may help to overcome these challenges and accelerate the development of safe and effective natural product-based therapies for patients with neurodegenerative diseases. Drug development is a critical aspect of natural product research for the treatment of neurodegenerative diseases. One of the most significant challenges is the complexity of natural products, which often contain multiple active ingredients that may have synergistic or antagonistic effects. Identifying the specific compounds responsible for the observed effects can be challenging, but it is essential for developing safe and effective drugs. To overcome this challenge, researchers use various techniques such as bioassay-guided fractionation, which involves separating the mixture into different fractions and testing each fraction for activity. This method allows researchers to isolate the active ingredient and determine its structure. Another approach is to use advanced analytical techniques, such as high-performance liquid chromatography and mass spectrometry, to identify the active compounds in natural products.

Another significant challenge associated with natural products is their poor bioavailability, which can limit their effectiveness as drugs. Bioavailability refers to the amount of a drug that reaches the bloodstream and the target tissues, and it depends on several factors, such as the route of administration, solubility, and stability. Many natural products are poorly soluble in water, which can limit their absorption in the gut. To overcome this challenge, researchers can modify natural products chemically or develop synthetic analogs that are more potent and have better pharmacokinetic properties. Natural products are also susceptible to contamination and adulteration, which can compromise their safety and efficacy. Quality control measures, such as the use of standardized extracts and analytical methods, are necessary to ensure the safety and consistency of natural product-based drugs. Standardization involves developing consistent and reproducible methods for producing natural products with a consistent composition and quality. In recent years, there have been significant advancements in the development of natural product-based drugs for the treatment of neurodegenerative diseases. For example, a standardized extract of *Ginkgo biloba*, EGb 761, has been developed as a drug for Alzheimer's disease. EGb 761 contains several active compounds, including terpenoids and flavonoids, that have neuroprotective effects. Another natural product-based drug, Huperzine A, derived from the club moss *Huperzia serrata*, has been developed for the treatment of Alzheimer's disease.

In conclusion, natural products offer a promising area of research for the development of treatments for neurodegenerative diseases. While there are several challenges associated with their use as drugs, advances in pharmacognosy, chemistry, and clinical medicine may help to overcome these challenges and accelerate the development of safe and effective natural product-based therapies for patients with neurodegenerative diseases. Standardization and quality control measures are crucial for ensuring the safety and efficacy of natural product-based drugs.

## 9. Challenges and Future Directions

Despite the promise of natural products as potential treatments for neurodegenerative diseases, several challenges remain. One challenge is the lack of standardization and quality control of natural product extracts, which can lead to variability in their composition and efficacy. Another challenge is the limited understanding of the optimal dosing, duration, and timing of natural product treatments. Additionally, regulatory and financial barriers can make it difficult to develop natural products as drugs. Future directions in this field include the identification and characterization of additional novel natural products with neuroprotective activity, as well as the optimization of natural product combinations and derivatives for improved efficacy and reduced toxicity. Advances in technology, such as high-throughput screening and bioinformatics, may help to accelerate the discovery of new natural products. Moreover, interdisciplinary collaborations between pharmacognosists, neuroscientists, chemists, and clinicians may lead to innovative approaches to developing natural product-based therapies for neurodegenerative diseases.

Natural products offer a promising area of research for the development of treatments for neurodegenerative diseases, but there is still much to be learned about their mechanisms of action and potential therapeutic uses. Future research may focus on identifying the active ingredients responsible for the observed effects of natural products, as well as developing more potent and bioavailable analogs. Combination therapies may also be explored, with natural products used in combination with other therapies such as conventional drugs or lifestyle interventions, to enhance their therapeutic effects. In addition, large-scale clinical trials will be necessary to determine the safety and efficacy of natural product-based treatments for neurodegenerative diseases. Further research on natural products for the treatment of neurodegenerative diseases may include the identification of new compounds and the optimization of existing natural products for better bioavailability and efficacy. Additionally, natural product combinations may be explored to examine their synergistic effects with conventional drugs. Another important area of research is the identification of biomarkers for neurodegenerative diseases, which can help identify patients who are at risk of developing these conditions and monitor disease progression. Natural products may play a role in the development of new biomarkers, due to their ability to target multiple pathways involved in neurodegeneration.

Neurodegenerative diseases are a group of disorders characterized by the progressive loss of neurons in the brain and spinal cord, leading to a decline in cognitive and motor function. These diseases, which include Alzheimer's, Parkinson's, and Huntington's disease, are a major public health concern and affect millions of people worldwide. Despite decades of research, there are currently no cures for these diseases, and available treatments are limited in their efficacy and often associated with significant side effects. One promising area of research for the development of treatments for neurodegenerative diseases is the use of natural products. Natural products are compounds that are derived from plants, animals, and microorganisms and have been used for centuries in traditional medicine. In recent years, there has been growing interest in the potential of natural products to prevent or treat neurodegenerative diseases, due to their ability to target multiple pathways involved in neurodegeneration.

However, there are several challenges associated with the use of natural products as drugs. One of the main challenges is the lack of standardization and quality control of natural product extracts. Natural products are often complex mixtures of compounds, which can make it difficult to identify the active ingredient responsible for the observed effects. Moreover, the composition of natural product extracts can vary depending on factors such as geographic

location, climate, and season, which can lead to variability in their efficacy. Another challenge is the limited understanding of the optimal dosing, duration, and timing of natural product treatments. Natural products may have different pharmacokinetic and pharmacodynamic properties than conventional drugs, and there is a need for more research to determine the optimal dosing and administration regimens for natural product-based treatments.

In addition to scientific challenges, there are also regulatory and financial barriers that can make it difficult to develop natural products as drugs. Natural products are often viewed as dietary supplements rather than drugs, which can make it difficult to obtain regulatory approval for their use as treatments for neurodegenerative diseases. Moreover, the development of natural products as drugs can be expensive, and there is often limited financial support available for this type of research.

Despite these challenges, there are several promising areas of future development for natural product-based therapies for neurodegenerative diseases. One area is the identification and characterization of additional novel natural products with neuroprotective activity. Advances in technology, such as high-throughput screening and bioinformatics, may help to accelerate the discovery of new natural products with potential therapeutic applications.

Another area of research is the optimization of natural product combinations and derivatives for improved efficacy and reduced toxicity. Natural products may be used in combination with other therapies such as conventional drugs or lifestyle interventions, to enhance their therapeutic effects. Moreover, natural product derivatives may be developed that are more potent and have better pharmacokinetic properties than the parent compounds. Large-scale clinical trials will be necessary to determine the safety and efficacy of natural product-based treatments for neurodegenerative diseases. These trials will need to be designed to address the challenges associated with natural products, such as the lack of standardization and the need for optimal dosing regimens. Additionally, the identification of biomarkers for neurodegenerative diseases may help to identify patients who are at risk of developing these conditions and monitor disease progression. Natural products may play a role in the development of new biomarkers, due to their ability to target multiple pathways involved in neurodegeneration.

Overall, natural products offer a rich source of potential therapies for the treatment of neurodegenerative diseases. While there are several challenges associated with their use as drugs, advances in pharmacognosy, chemistry, and clinical medicine may help to overcome these challenges and accelerate the development of safe and effective natural product-based therapies for patients with neurodegenerative diseases. Continued research in this area may lead to new and effective treatments for these devastating conditions.

## 10. Conclusion

Natural products offer a promising avenue for the development of safe and effective treatments for neurodegenerative diseases. Despite the challenges associated with the use of natural products as drugs, advances in pharmacognosy, chemistry, and clinical medicine provide an opportunity to overcome these challenges and accelerate the development of natural product-based therapies. Through interdisciplinary collaborations and the use of innovative technologies, researchers can identify and characterize new compounds, optimize existing natural products, and explore combination therapies to enhance their therapeutic effects. Additionally, the identification of biomarkers for neurodegenerative diseases can aid in early diagnosis and monitoring of disease progression. With continued research, natural products

have the potential to provide much-needed treatments for patients suffering from neurodegenerative diseases.

One of the most promising areas of research is the identification of new natural products with neuroprotective activity. Advances in technology, such as high-throughput screening and bioinformatics, have made it easier to identify novel compounds and accelerate drug discovery. By exploring the chemical diversity of natural products and characterizing their mechanisms of action, we can identify new leads for the development of neuroprotective drugs. Another important area of research is the optimization of natural product derivatives and combinations.

Finally, the development of natural product-based therapies for neurodegenerative diseases requires interdisciplinary collaborations and partnerships. Pharmacognosists, chemists, neuroscientists, clinicians, and regulators all have important roles to play in advancing this field. By working together, we can overcome the challenges and accelerate the translation of natural product research into clinical practice. Continued research and collaboration in this field may lead to new and effective treatments for these devastating conditions.

**References:**

1. Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M. P., Klein, W. L., ... & Mucke, L. (2006). Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. The Journal of Neuroscience, 26(50), 13102-13113.

2. Liu, X., & Huang, X. (2019). Neuroprotective effects of natural compounds on Parkinson's disease. Natural Products and Bioprospecting, 9(2), 123-144.

3. Peng, C., Li, J., Zhang, K., Liu, L., Deng, Z., Zhang, Y., ... & Xiao, P. (2019). Natural products and their derivatives: promising modulators of protein aggregation. Current Medicinal Chemistry, 26(1), 79-107.

4. Shanmuganathan, B., & Subramanian, P. (2019). Bioactive compounds and their potential neuroprotective role in Parkinson's disease. Nutritional Neuroscience, 22(5), 297-311.

5. Zhu, L., & Sun, Z. (2019). Neuroprotective effects of natural products on cerebral ischemia/reperfusion injury. Current Neuropharmacology, 17(3), 214-229.

6. Reddy, V. P., & Zhu, X. (2016). Perry G. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. British Journal of Pharmacology, 174(11), 1325-1338.

7. Zhao, Y., Zhao, H., & Liu, X. (2019). Dietary natural products for prevention and treatment of Parkinson's disease: a systematic review. Evidence-Based Complementary and Alternative Medicine, 2019.

8. Liu, X., Ye, K., Weinreb, O., Goldbaum, O., & Levy, A. (2017). Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration. RSC Advances, 7(5), 2725-2733.

9. Wang, W., Wu, Q., Zhang, Y., Zhang, X., Chen, X., Liu, X., ... & Xu, Y. (2019). Neuroprotective effects of natural compounds on Alzheimer's disease. Frontiers in Pharmacology, 10, 135.

10. Dinda, B., & Dinda, S. (2017). Natural products and their derivatives against neurodegenerative diseases: a comprehensive overview. Advances in Neurobiology, 14, 1-14.

11. Abidin, S. A. Z., Yaacob, N. S., & Nordin, N. (2020). Natural products as potential therapeutics for Alzheimer's disease: A review. Frontiers in Pharmacology, 11, 522.

12. Cacciatore, I., Baldassarre, L., Fornasari, E., Mollica, A., & Pinnen, F. (2018). Recent advances in the treatment of neurodegenerative diseases based on Ginkgo biloba constituents. Fitoterapia, 129, 92-102.

13. Chen, S., Zhou, H., & Xu, Z. (2019). Advances in targeting oxidation stress in neurological diseases: Natural products and main active components. Frontiers in Pharmacology, 10, 763.

14. Fernández-Moriano, C., González-Burgos, E., Iglesias, I., & Gómez-Serranillos, M. P. (2020). Natural products for Alzheimer's disease therapy: A comprehensive review. Current Neuropharmacology, 18(2), 115-139.

15. Han, Y., Sun, L., Yuan, Y., Yu, R., & Zhang, Y. (2020). Natural products as a source for the discovery of Alzheimer's disease therapeutics. Current Medicinal Chemistry, 27(1), 141-175.

16. Lai, S. L., Teoh, S. L., Ch'ng, E. S., & Abdul-Rahman, P. S. (2019). Recent advances in the identification of natural products as potential drug candidates for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery, 14(11), 1169-1188.

17. Li, L., Zhang, Q., Yang, X., Chang, Y., & Zhang, Y. (2019). Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Anti-Cancer Agents in Medicinal Chemistry, 19(8), 1011-1021.

18. Pal, S., Biswas, J., Bhattacharjee, S., Mukherjee, S., & Das, G. (2020). Role of natural products in neurodegenerative disorders. Current Neuropharmacology, 18(2), 114-121.

19. Pandey, S., Cabral, D. J., & Souza, G. R. (2019). Potential use of natural products in the treatment of Alzheimer's disease. Current Topics in Medicinal Chemistry, 19(32), 2912-2926.

20. Sahoo, S. K., Biswas, A., Kumar Mishra, B., & Pandey, A. (2020). Natural products as a potential source for the treatment of Alzheimer's disease: A review. International Journal of Neuroscience, 130(11), 1071-1086.

21. Zhuang P, Zhang Y, Cui G, Bian Y, Zhang M, Zhang L. Natural products for the prevention and treatment of Alzheimer's disease. Curr Top Med Chem. 2016;16(17):1943-1953. doi: 10.2174/1568026616666160222102434

22. Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM. Neuroprotective effects of chalcones: from chemistry to medicine. Neurochem Int. 2016;100:1-10. doi: 10.1016/j.neuint.2016.07.007

23. Lin YC, Ueng YF, Wu JS. Molecular mechanisms of natural products on the treatment of Alzheimer's disease. Chem Biol Interact. 2017;275:85-94. doi: 10.1016/j.cbi.2017.06.006

24. Pan SY, Zhou SF, Gao SH, et al. New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med. 2013;2013:627375. doi: 10.1155/2013/627375

25. da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA. Natural products inhibitors of the enzyme acetylcholinesterase. Nat Prod Rep. 2012;29(11):1180-1202. doi: 10.1039/c2np20045j

26. Liu M, Zhang X, Cai Q, et al. Neuroprotective effects of natural products against Alzheimer's disease. Curr Top Med Chem. 2016;16(17):1954-1972. doi: 10.2174/1568026616666160222103404

27. Li Y, Shi Z, Rada M, et al. Natural products as neuroprotective agents for preventing neurodegenerative diseases. Aging Dis. 2020;11(3):716-733. doi: 10.14336/AD.2019.0907

28. Gao Y, Chu SF, Li JH, et al. Natural products from traditional chinese medicines with neuroprotective effects against neurodegenerative diseases. Chem Biodivers. 2020;17(4):e1900549. doi: 10.1002/cbdv.201900549

29. Orhan IE, Senol FS, Gulpinar AR, Kartal M, Sener B. Potential therapeutic applications and delivery strategies for natural products in Parkinson's disease therapy. Curr Drug Metab. 2018;19(7):608-622. doi: 10.2174/1389200219666180327094334

30. Rocha JBT, Valadares YMD, Pereira P, et al. Phytochemicals as promising drugs for the prevention and treatment of dementia. Curr Neuropharmacol. 2020;18(6):542-557. doi: 10.2174/1570159X18666200519111518

31. Zhang, Y., Huang, N., Yan, F., Jin, H., Zhou, S. Y., Shi, J. S., & Jin, F. (2020). Recent advances in natural products from plants for the treatment of neurodegenerative diseases. Frontiers in aging neuroscience, 12, 525.

32. Gu, X. L., Long, C. X., Sun, L., Cong, Y. S., & Xie, Y. (2010). Curcumin protects PC12 cells from corticosterone-induced cytotoxicity: possible involvement of the ERK1/2 pathway. Basic & clinical pharmacology & toxicology, 107(2), 668-672.

33. Ahmed, T., Enam, S. A., Gilani, A. H., & Ahmed, B. (2021). Inhibitors of cholinesterases from natural sources: a review of their potential in Alzheimer's disease therapeutics. Pharmaceutical biology, 59(1), 1-16.

34. Tian, T., Li, X., Zhang, J., & Liang, Y. (2021). Natural products as potential treatment options for Alzheimer's disease: molecular mechanisms and clinical implications. Current medicinal chemistry, 28(10), 1973-1993.

35. Behl, T., Kaur, I., & Kotwani, A. (2017). Implication of natural products in future drug development for the treatment of Alzheimer's disease: a review. Journal of dietary supplements, 14(3), 305-317.

36. Islam, M. T. (2019). Natural products and their derivatives against neurodegenerative diseases: Preclinical evidence. Current pharmaceutical design, 25(25), 2729-2750.

37. Vareed, S. K., Kakarala, M., Ruffin, M. T., Crowell, J. A., Normolle, D. P., Djuric, Z., ... & Brenner, D. E. (2008). Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer epidemiology, biomarkers & prevention, 17(6), 1411-1417.

38. Ahmed, T., Enam, S. A., Gilani, A. H., & Ahmed, B. (2019). Potential of natural products in the treatment of Alzheimer's disease: narrative review. Current clinical pharmacology, 14(4), 231-238.

39. Bredesen, D. E., John, V., & Galvan, V. (2020). Importance of a multi-modal approach in Alzheimer's disease: an update on the pharmacological management of Alzheimer's disease. Journal of Alzheimer's Disease, 76(1), 1-10.

40. Lim, K. L., & Ng, C. H. (2020). Genetics of Parkinson disease in Asia and challenges in the era of precision medicine. Journal of Parkinson's Disease, 10(3), 977-990.

41. Amin FU, Shah SA, Kim MO. Vanillic acid attenuates Aβ1–42-induced oxidative stress and cognitive impairment in mice. Sci Rep. 2017;7:40753. doi:10.1038/srep40753

42. Liu Y, Li J, Wang X, et al. Anti-inflammatory effects of thymoquinone in microglial cells. J Neuroimmunol. 2011;253(1–2):40-45. doi:10.1016/j.jneuroim.2012.08.007

43. Wang Y, Mao X, Yu X, et al. Baicalein protects cortical neurons from oxygen and glucose deprivation/reoxygenation. J Mol Neurosci. 2012;47(2):256-265. doi:10.1007/s12031-011-9686-5

44. Yan J, Hu Y, Feng J, et al. Ginsenoside Rd promotes neurogenesis in rat brain after transient focal cerebral ischemia via activation of PI3K/Akt pathway. Acta Pharmacol Sin. 2012;33(5):531-538. doi:10.1038/aps.2012.2

45. Xu X, Zhang Z, Yang Y, et al. Tanshinone II-A attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide. J Ethnopharmacol. 2013;147(1):111-118. doi:10.1016/j.jep.2013.02.014

46. Wang X, Zhang L, Yin J, et al. Neuroprotective effects of salidroside on focal cerebral ischemia/reperfusion injury involve the nuclear erythroid 2-related factor 2 pathway. Neural Regen Res. 2014;9(4):357-363. doi:10.4103/1673-5374.125342

47. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol attenuates microglial activation via SIRT1-SOCS1 pathway. Evid Based Complement Alternat Med. 2013;2013:1-15. doi:10.1155/2013/815418

48. Ye Q, Huang B, Zhang X, Zhu Y, Chen X. Astaxanthin protects against MPP(+)-induced oxidative stress in PC12 cells via the HO-1/NOX2 axis. BMC Neurosci. 2012;13(1):156. doi:10.1186/1471-2202-13-156

49. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer’s disease. Eur J Neurol. 2008;15(8):865-868. doi:10.1111/j.1468-1331.2008.02157 x

50. Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress—protective activity. Pharmaceuticals (Basel). 2010;3(1):188-224. doi:10.3390/ph3010188